Who are Cetrorelix and Leuprolide's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lupron, Micronor, Ultra-Long GnRH Agonists, GnRH agonist/antagonist, Half-Dose Depot Triptorelin, Gonapeptyl®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cetrorelix-and-leuprolide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Cetrorelix and Leuprolide — Competitive Intelligence Brief

Cetrorelix and Leuprolide (Cetrorelix and Leuprolide) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GnRH antagonist and GnRH agonist combination. Area: Reproductive Medicine / Fertility.

marketed GnRH antagonist and GnRH agonist combination GnRH receptor Reproductive Medicine / Fertility Small molecule Live · refreshed every 30 min

Target snapshot

Cetrorelix and Leuprolide (Cetrorelix and Leuprolide) — Instituto Valenciano de Infertilidad, IVI VALENCIA. Cetrorelix and leuprolide work together to suppress the pituitary-gonadal axis by blocking GnRH signaling, preventing premature luteinizing hormone surge during controlled ovarian hyperstimulation for assisted reproduction.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cetrorelix and Leuprolide TARGET	Cetrorelix and Leuprolide	Instituto Valenciano de Infertilidad, IVI VALENCIA	marketed	GnRH antagonist and GnRH agonist combination	GnRH receptor
Lupron	leuprorelin	Accord Healthcare S.L.U.	marketed	Gonadotropin Releasing Hormone Receptor Agonist	GnRH receptors	1985-01-01
Micronor	norethisterone	Johnson & Johnson	marketed	Progestin	GnRH receptors	1962-01-01
Ultra-Long GnRH Agonists	Ultra-Long GnRH Agonists	University of Palermo	marketed	GnRH agonist	GnRH receptor
GnRH agonist/antagonist	GnRH agonist/antagonist	Memorial Sloan Kettering Cancer Center	marketed	GnRH agonist/antagonist	GnRH receptor
Half-Dose Depot Triptorelin	Half-Dose Depot Triptorelin	Tehran University of Medical Sciences	marketed	GnRH agonist	GnRH receptor
Gonapeptyl®	Gonapeptyl®	University Hospital, Ghent	marketed	GnRH agonist	GnRH receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-03-22 — Lupron · 9617303 · US
2031-02-05 — Lupron · 8921326 · US

Sponsor landscape (GnRH antagonist and GnRH agonist combination class)

Instituto Valenciano de Infertilidad, IVI VALENCIA · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cetrorelix and Leuprolide — Competitive Intelligence Brief. https://druglandscape.com/ci/cetrorelix-and-leuprolide. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab